share_log

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Benzinga ·  Nov 26, 2024 00:07

Cassava Sciences(NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock's crash Sunday night.

What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, sending shares significantly lower to start the trading week.

The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment